tradmap

CCCC C4 Therapeutics, Inc.

$4.14 +5.88%

Healthcare · Biological Products, (No Diagnostic Substances)

C4 Therapeutics, Inc. (CCCC) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $458 million. Shares last traded at $4.14, 11.0% below their 52-week high. Over the past year the stock is up 178.8%. Net profit margin is -292.1%, below the peer median of 6.3%. Revenue grew 1.0% year over year.

Market Cap
$458M
Shares Out
110.6M
EPS (TTM)
$-2.49
P/E Ratio
P/S Ratio
12.73
P/B Ratio
1.95
Dividend / Share
Dividend Yield
52-Week High
$4.65
52-Week Low
$1.36
Volume
170,220
Avg Vol (3m)
159,570.698

Performance

1W
+6.98%
1M
+32.91%
3M
+55.64%
6M
+83.19%
YTD
+114.51%
1Y
+178.79%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
61.24
SMA (50)
$3.36
SMA (200)
$2.66
Price vs SMA50
+23.33%
Price vs SMA200
+55.69%
ATR (14)
$0.34

Financials

Revenue
$36M
Net Income
$-105M
Gross Margin
Operating Margin
-320.5%
Net Margin
-292.1%
Return on Equity
-44.8%
Return on Assets
-31.9%
Current Ratio
9.00
Debt / Equity
0.00
Revenue Growth (YoY)
+1.0%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.20 2026-05-12
FY 2025 $-1.27 2026-02-26
Q3 2025 $-1.18 2025-11-06
Q2 2025 $-0.74 2025-08-07
Q1 2026 $-0.37 2026-05-12
FY 2025 $-1.52 2026-02-26

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CCCC vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
12.73 / 5.21 med
+144% premium
Net margin vs peers
-292.1% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.